ExpreS2ion Biotech Holding AB (publ) (FRA:5JD0)

Market Cap	2.74M -48.7%
Revenue (ttm)	2.19M +136.7%
Net Income	-3.24M
EPS	-0.14
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0852
Previous Close	0.0948
Day's Range	0.0852 - 0.0852
52-Week Range	0.0280 - 2.0500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About FRA:5JD0

ExpreS2ion Biotech Holding AB (publ), a clinical-stage biotechnology company, develops protein-based immunotherapies and vaccines for oncology and infectious diseases in the Nordics and internationally. The company’s lead asset is ES2B-C001, an immunotherapy candidate, which is in Phase 1 clinical trials for breast cancer that targets the human epidermal growth factor receptor 2, as well as vaccines for Nipah virus, Malaria, and influenza. It also offers GlycoX-S2, a glyco-engineered variants of the ExpreS2 platform to modify glycosylation patt...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 19
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5JD0

Financial Performance

In 2025, FRA:5JD0's revenue was 12.21 million, an increase of 56.00% compared to the previous year's 7.83 million. Losses were -38.09 million, 5.68% more than in 2024.

Financial numbers in SEK

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error